Clinical trial
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
NCT00092534 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00092534 |
|---|---|
| Title | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) |
| Official title | A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE… |
| Acronym | FUTURE II |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Genital Warts |
| Intervention type | Biological |
| Interventions | Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine, Matching Placebo |
| Enrollment | 12,167 |
| Start date | Jun 14, 2002 |
| Primary completion | Jul 31, 2007 |
| Completion | Jun 13, 2025 |
| First posted | Sep 28, 2004 |
| Last update posted | Aug 1, 2025 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: